{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-24-000043","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.304382+00:00","generated_at":"2026-05-31T12:08:40.467153+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Halozyme beats Q2 with $231M revenue, $0.91 non-GAAP EPS; reiterates raised 2024 outlook","bullets":["Revenue $231M (+5% YoY), net income $93M (+24%), GAAP EPS $0.72, non-GAAP EPS $0.91.","Royalty revenue $124.9M (+12% YoY) led by Phesgo, VYVGART Hytrulo, and Teriparatide launches.","Reiterated FY2024 guidance: rev $935-1015M, adj EBITDA $555-615M, non-GAAP EPS $3.65-4.05.","Partner approvals: Ocrevus SC (EU/UK), VYVGART Hytrulo for CIDP (US); BMS nivolumab SC PDUFA Dec 29, 2024.","Completed $250M ASR (6.5M shares at $38.35); new EU patent extends ENHANZE royalty through March 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-24-000043","json":"https://secwatch.observer/filing/0001159036-24-000043.json","markdown":"https://secwatch.observer/filing/0001159036-24-000043.md","text":"https://secwatch.observer/filing/0001159036-24-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000043/0001159036-24-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000043/halo-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:08:40.467153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}